Brief: Neurizon Therapeutics Says U.S. FDA Placed Co's Investigational New Drug Application Under Clinical Hold
17/01/2025 01:26
Jan 17 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* U.S. FDA PLACED CO'S INVESTIGATIONAL NEW DRUG APPLICATION
FOR
NUZ-001 UNDER CLINICAL HOLD
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO